Decision: Favourable

Study Title:

A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults with Familial Chylomicronemia Syndrome

  • NREC Code:

    22-NREC-CT-017

  • Decision:

    Favourable

  • Meeting Date:

    09/02/2022

  • Study Type:

    CT application

  • Principal Investigator:

    Dr Damien Griffin

  • PI Institution:

    University Hospital Galway

  • Sponsor:

    Arrowhead Pharmaceuticals, Inc.

Scroll to Top